Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2S)-2-amino-3-(([(2R,3R)-3-benzoyloxiran-2-yl]carbonyl)amino)propanoic acid
-
-
(2S)-2-amino-3-([(2E)-4-oxo-4-phenylbut-2-enoyl]amino)propanoic acid
-
-
(2S)-2-amino-3-([(2E)-4-oxopent-2-enoyl]amino)propanoic acid
-
-
(2S)-3-(([(2R,3R)-3-acetyloxiran-2-yl]carbonyl)amino)-2-aminopropanoic acid
-
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
(4S)-2-methyl-2-phenylpentane-1,4-diol
1'-N-methyl spiro[2'.2'']-acenaphthyleno-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.2'']-indane-1'',3''-dione-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.3'']-(4'',7''-dichloro)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.3'']-(5'',7''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.3'']-(5''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.3'']-(N-methyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.3'']-(N-phenyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
1'-N-methyl spiro[2'.3'']oxindolo-3'-cholestrylcarboxylate pyrrolidine
1,1'-[1,3,4-thiadiazole-2,5-diylbis[sulfanediyl(1-oxoethane-2,1-diyl)]]ditetrahydropyridazine-3,6-dione
-
1,2-anhydrohexitol 6-phosphate
-
mixture of the four diastereoisomers. Irreversible inactivation. D-fructose 6-phosphate and 2-amino-2-deoxyglucitol protect, L-glutamine does not
1-methyl 8-(2-oxopropyl) (2E,7S)-7-amino-4-oxooct-2-enedioate
-
ester derivative of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid, potent inhibitory activity against fungal glucosamine-6-phosphate synthase, good antifungal activity against Candida albicans
1-methyl 8-[(2R)-3-oxobutan-2-yl] (2E,7S)-7-amino-4-oxooct-2-enedioate
-
ester derivative of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid, potent inhibitory activity against fungal glucosamine-6-phosphate synthase, good antifungal activity against Candida albicans
2,2'-(1,3,4-thiadiazole-2,5-diyldisulfanediyl)bis[N-(pyrrolidin-1-yl)acetamide]
-
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
2-amino-2-deoxy-D-glucitol 6-phosphate
2-amino-2-deoxy-D-glucitol-6-phosphate
2-amino-2-deoxy-D-glucitol-6-phosphate dimethyl ester
-
-
2-amino-2-deoxy-D-mannitol 6-phosphate
2-amino-2-deoxy-D-mannitol-6-phosphate
2-Amino-2-deoxyglucitol 6-phosphate
-
competitive with respect to D-fructose 6-phosphate
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
4,4'-dithiodipyridine
-
inactivation reversed by dithiothreitol. Competitive with respect to L-glutamine. Non-competitive with respect to D-fructose 6-phosphate
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
4-(furan-2-ylcarbonyl)-3-hydroxy-5-(4-phenoxyphenyl)-1-(pyridin-3-ylmethyl)-1,5-dihydro-2H-pyrrol-2-one
20% inhibition at 0.1 mM
4-Glutamylhydroxamate
-
-
5,5'-dithionitrobenzoic acid
5-phospho-D-arabinoamide
-
-
6,6'-Dithiodinicotinic acid
6,7-bis(2-methoxyphenyl)-10-methyl-1,4,7,12-tetrahydro-6H-chromeno[4,3-d][1,2,4]triazolo[1,5-a]pyrimidine
70% inhibition at 0.1 mM
6-diazo-5-oxo-L-norleucine
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
8-(3,3-dimethyl-2-oxobutyl) 1-methyl (2E,7S)-7-amino-4-oxooct-2-enedioate
-
ester derivative of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid, potent inhibitory activity against fungal glucosamine-6-phosphate synthase, good antifungal activity against Candida albicans
arabinose oxime 5-phosphate
-
inhibitor of the sugar isomerising domain
cholest-5-en-3-yl 1,3-dioxo-1,1',2',3,5',6',7',7'a-octahydrospiro[indene-2,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 1-methyl-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 2-oxo-1',2',5',6',7',7'a-hexahydro-2H-spiro[acenaphthylene-1,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 2-oxo-1-phenyl-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 4,7-dichloro-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 5,7-dibromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
cholest-5-en-3-yl 5-bromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
Congo red
CR, affects the growth, morphology, and activity of glucosamine-6-phosphate synthase in human pathogenic fungus Sporothrix schenckii. Under conditions of yeast development, 0.015 mM CR abolishes conidia germination, but when yeast cells are first obtained in the absence of the dye and then post-incubated in its presence, yeasts rapidly differentiate into mycelial cells. On the other hand, under conditions of mycelium development, 0.150 mM CR do not affect conidia germination, but filamentous cells undergo structural changes characterized by a distorted cell wall contour, the loss of polarity and the formation of red-pigmented, hyphal globose structures. Under these conditions, CR also induces a significant and transient increase in the activity of GlcN-6-P synthase, an essential enzyme in cell wall biogenesis
D-glucitol 6-phosphate
-
competitive with respect to D-fructose 6-phosphate
D-glucosamine 6-phosphate
-
negative feedback-regulation at post-transcriptional level. The biological function of small RNA GlmZ is to positively control the enzyme's mRNA in response to D-glucosamine 6-phosphate concentrations. YhbJ, a gene of the rpoN operon, negatively regulates GlmZ
D-glucosamine-6-phosphate
-
1 mM, about 50% loss of activity
dihydroxyacetone phosphate
-
weak
DL-delta-1-pyrroline-5-carboxylate
-
competitive with respect to L-glutamine
ethyl 2-[2-(3-bromophenyl)-3-[(4-fluorophenyl)carbonyl]-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrol 1-yl]-4-methyl-1,3-thiazole-5-carboxylate
70% inhibition at 0.1 mM
ethyl 2-[3-[(4-fluorophenyl)carbonyl]-4-hydroxy-2-(4-methoxyphenyl)-5-oxo-2,5-dihydro-1H pyrrol-1-yl]-4-methyl-1,3-thiazole-5-carboxylate
70% inhibition at 0.1 mM
fructose 1,6-diphosphate
-
weak
glyceraldehyde 3-phosphate
-
50% inhibition at 0.2 mM
Glyoxal
-
50% inhibition at 0.03 mM
L-2,3-diaminopropanoic acid
L-alpha-glycerophosphate
-
weak
Mercuric chloride
-
84% inhibition at 1 mM
methyl (2E)-4-([(2S)-2,3-diamino-3-oxopropyl]amino)-4-oxobut-2-enoate
-
-
methyl (2E)-4-([(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino)-4-oxobut-2-enoate
-
-
N-acetyl-2-amino-2-deoxy-D-glucitol-6-phosphate
-
-
N-iodoacetylglucosamine 6-phosphate
-
D-fructose 6-phosphate protects
N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid
N3-bromoacetyl-L-2,3-diaminopropanoic acid
N3-chloroacetyl-L-2,3-diaminopropanoic acid
N3-fumaramoyl-L-2,3-diaminopropanoic acid
N3-fumaroyl-L-2,3-diaminopropanoic acid
N3-fumarylcarboxyamido-L-2,3-diaminopropionic acid
N3-iodoacetyl-L-2,3-diaminopropanoic acid
N3-L-trans-epoxysuccinamoyl-L-2,3-diaminopropanoic acid
-
inhibitor of the glutamine binding site
N4-(4-Methoxyfumaroyl)-L-2,4-diaminobutanoic acid
-
-
p-hydroxymercuribenzoate
-
-
pyridoxamine-5'-phosphate
-
-
Tolbutamide
-
80% inhibition at 2 mg/ml
UDP-N-acetyl-alpha-D-glucosamine
-
-
uridine 5'-diphospho-N-acetyl-D-glucosamine
-
-
uridine 5'-diphospho-N-acetylglucosamine
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
-
(3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol
-
(4S)-2-methyl-2-phenylpentane-1,4-diol
-
(4S)-2-methyl-2-phenylpentane-1,4-diol
-
(4S)-2-methyl-2-phenylpentane-1,4-diol
-
(4S)-2-methyl-2-phenylpentane-1,4-diol
-
(4S)-2-methyl-2-phenylpentane-1,4-diol
-
(4S)-2-methyl-2-phenylpentane-1,4-diol
-
1'-N-methyl spiro[2'.2'']-acenaphthyleno-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.2'']-acenaphthyleno-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.2'']-acenaphthyleno-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.2'']-acenaphthyleno-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.2'']-indane-1'',3''-dione-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.2'']-indane-1'',3''-dione-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.2'']-indane-1'',3''-dione-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.2'']-indane-1'',3''-dione-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(4'',7''-dichloro)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(4'',7''-dichloro)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(4'',7''-dichloro)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(4'',7''-dichloro)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(5'',7''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(5'',7''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(5'',7''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(5'',7''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(5''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(5''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(5''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(5''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(N-methyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(N-methyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(N-methyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(N-methyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(N-phenyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(N-phenyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']-(N-phenyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']-(N-phenyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1'-N-methyl spiro[2'.3'']oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
1'-N-methyl spiro[2'.3'']oxindolo-3'-cholestrylcarboxylate pyrrolidine
-
-
1,1'-dithiodiformamidine
-
irreversible inhibition
1,1'-dithiodiformamidine
-
irreversible inhibition
1,1'-dithiodiformamidine
-
irreversible inhibition
1,1'-dithiodiformamidine
-
irreversible inhibition
1,1'-dithiodiformamidine
-
irreversible inhibition
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
-
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
-
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
-
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
-
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
-
2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol
-
2-amino-2-deoxy-D-glucitol 6-phosphate
-
-
2-amino-2-deoxy-D-glucitol 6-phosphate
-
-
2-amino-2-deoxy-D-glucitol-6-phosphate
-
-
2-amino-2-deoxy-D-glucitol-6-phosphate
IC50: 0.056 mM
2-amino-2-deoxy-D-glucitol-6-phosphate
-
inhibitor of the sugar isomerising domain
2-amino-2-deoxy-D-glucitol-6-phosphate
-
2-amino-2-deoxy-D-mannitol 6-phosphate
-
-
2-amino-2-deoxy-D-mannitol 6-phosphate
-
2-amino-2-deoxy-D-mannitol-6-phosphate
-
-
2-amino-2-deoxy-D-mannitol-6-phosphate
-
exhibits stronger affinity for the sugar-binding site of GlcN-6-P synthase than 2-amino-2-deoxy-D-glucitol-6-phosphate
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
-
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
-
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
-
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
-
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
-
3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol
-
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol
-
5,5'-dithionitrobenzoic acid
-
irreversible inhibition
5,5'-dithionitrobenzoic acid
-
irreversible inhibition
5,5'-dithionitrobenzoic acid
-
irreversible inhibition
5,5'-dithionitrobenzoic acid
-
irreversible inhibition
5,5'-dithionitrobenzoic acid
-
inactivation reversed by dithiothreitol
5,5'-dithionitrobenzoic acid
-
irreversible inhibition
6,6'-Dithiodinicotinic acid
-
irreversible inhibition
6,6'-Dithiodinicotinic acid
-
irreversible inhibition
6,6'-Dithiodinicotinic acid
-
irreversible inhibition
6,6'-Dithiodinicotinic acid
-
irreversible inhibition
6,6'-Dithiodinicotinic acid
-
irreversible inhibition
6-diazo-5-oxo-L-norleucine
-
competitive with respect to L-glutamine
6-diazo-5-oxo-L-norleucine
-
-
6-diazo-5-oxo-L-norleucine
-
-
6-diazo-5-oxo-L-norleucine
2 mM
6-diazo-5-oxo-L-norleucine
-
-
6-diazo-5-oxo-L-norleucine
-
inhibitor of the glutamine binding site
6-diazo-5-oxo-L-norleucine
-
-
6-diazo-5-oxo-L-norleucine
-
-
6-diazo-5-oxo-L-norleucine
-
-
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
-
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
-
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
-
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
-
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
-
7-methoxy-2,3-dihydro-2-phenyl-4 quinolone
-
anticapsin
-
L-glutamine protects, irreversible inhibition
anticapsin
-
L-glutamine protects, irreversible inhibition
anticapsin
-
inhibitor of the glutamine binding site
anticapsin
-
L-glutamine protects, irreversible inhibition
anticapsin
-
L-glutamine protects, irreversible inhibition
azaserine
-
weak
catechin
-
cholest-5-en-3-yl 1,3-dioxo-1,1',2',3,5',6',7',7'a-octahydrospiro[indene-2,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 1,3-dioxo-1,1',2',3,5',6',7',7'a-octahydrospiro[indene-2,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 1,3-dioxo-1,1',2',3,5',6',7',7'a-octahydrospiro[indene-2,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 1,3-dioxo-1,1',2',3,5',6',7',7'a-octahydrospiro[indene-2,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 1-methyl-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 1-methyl-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 1-methyl-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 1-methyl-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 2-oxo-1',2',5',6',7',7'a-hexahydro-2H-spiro[acenaphthylene-1,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 2-oxo-1',2',5',6',7',7'a-hexahydro-2H-spiro[acenaphthylene-1,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 2-oxo-1',2',5',6',7',7'a-hexahydro-2H-spiro[acenaphthylene-1,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 2-oxo-1',2',5',6',7',7'a-hexahydro-2H-spiro[acenaphthylene-1,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 2-oxo-1-phenyl-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 2-oxo-1-phenyl-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 2-oxo-1-phenyl-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 2-oxo-1-phenyl-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 4,7-dichloro-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 4,7-dichloro-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 4,7-dichloro-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 4,7-dichloro-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 5,7-dibromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 5,7-dibromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 5,7-dibromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 5,7-dibromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 5-bromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 5-bromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
cholest-5-en-3-yl 5-bromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
cholest-5-en-3-yl 5-bromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate
-
-
iodoacetamide
-
irreversible inhibition
iodoacetamide
-
irreversible inhibition
iodoacetamide
-
irreversible inhibition
iodoacetamide
-
irreversible inhibition
iodoacetamide
-
irreversible inhibition
L-2,3-diaminopropanoic acid
-
-
L-2,3-diaminopropanoic acid
-
-
L-2,3-diaminopropanoic acid
-
-
L-ascorbic acid
-
luteolin
-
methylglyoxal
-
50% inhibition at 0.01 mM, non competitive
methylglyoxal
-
inhibits preincubated enzyme less profoundly than the untreated enzyme
N-ethylmaleimide
-
irreversible inhibition
N-ethylmaleimide
-
irreversible inhibition
N-ethylmaleimide
-
irreversible inhibition
N-ethylmaleimide
-
irreversible inhibition
N-ethylmaleimide
-
78% inhibition at1 mM
N-ethylmaleimide
-
irreversible inhibition
N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid
-
-
N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid
-
acts as active-site-directed inactivator blocking the N-terminal, glutamine-binding domain of the enzyme; inhibitor of the glutamine binding site
N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid
-
L-glutamine and some analogs protect
N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid
selective
N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid
-
N3-bromoacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-bromoacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-bromoacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-bromoacetyl-L-2,3-diaminopropanoic acid
-
inhibitor of the glutamine binding site
N3-chloroacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-chloroacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-chloroacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-fumaramoyl-L-2,3-diaminopropanoic acid
-
-
N3-fumaramoyl-L-2,3-diaminopropanoic acid
-
-
N3-fumaroyl-L-2,3-diaminopropanoic acid
-
-
N3-fumaroyl-L-2,3-diaminopropanoic acid
-
-
N3-fumarylcarboxyamido-L-2,3-diaminopropionic acid
-
competitive with L-glutamine
N3-fumarylcarboxyamido-L-2,3-diaminopropionic acid
-
-
N3-iodoacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-iodoacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
N3-iodoacetyl-L-2,3-diaminopropanoic acid
-
competitive with respect to L-glutamine
naringenin
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
84% inhibition at 0.1 mM
UDP-N-acetylglucosamine
-
competitive with respect to D-fructose 6-phosphate, non-competitive with respect to L-glutamine
UDP-N-acetylglucosamine
-
partial
UDP-N-acetylglucosamine
-
feed-back inhibition
UDP-N-acetylglucosamine
-
weak
UDP-N-acetylglucosamine
-
-
UDP-N-acetylglucosamine
-
40% inhibition at 1 mM
UDP-N-acetylglucosamine
maximum inhibition at 1 mM
UDP-N-acetylglucosamine
-
competitive inhibitor with respect to D-fructose 6-phosphate
additional information
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
a series of covalent cholesterol-spiro pyrrolidine/pyrrolizidine heterocyclic hybrids possessing biologically active oxindole, indanedione, and acenaphthylene-1-one are synthesized as enzyme inhibitors by the reaction of C3-beta-cholesteroalacrylate with heterocyclic di- and tri-ketones, the compounds are obtained as a single isomer in good yield through a stereo- and regioselective 1,3-dipolar cycloaddition methodology, method overview. Analysis of in vitro antibacterial activity, and inhibitory activity against highly pathogenic Gram-positive and Gram-negative bacteria. Automated in silico molecular docking analysis of cadidates in order to validate their effective orientation as inhibitors bound in the active site of glucosamine-6-phosphate synthase (1XFF) enzyme
-
additional information
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
no inhibition by 0.1 mM c3, 4, 6, 9, 12, 13
-
additional information
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
a series of covalent cholesterol-spiro pyrrolidine/pyrrolizidine heterocyclic hybrids possessing biologically active oxindole, indanedione, and acenaphthylene-1-one are synthesized as enzyme inhibitors by the reaction of C3-beta-cholesteroalacrylate with heterocyclic di- and tri-ketones, the compounds are obtained as a single isomer in good yield through a stereo- and regioselective 1,3-dipolar cycloaddition methodology, method overview. Analysis of in vitro antibacterial activity, and inhibitory activity against highly pathogenic Gram-positive and Gram-negative bacteria. Automated in silico molecular docking analysis of cadidates in order to validate their effective orientation as inhibitors bound in the active site of glucosamine-6-phosphate synthase (1XFF) enzyme
-
additional information
a series of covalent cholesterol-spiro pyrrolidine/pyrrolizidine heterocyclic hybrids possessing biologically active oxindole, indanedione, and acenaphthylene-1-one are synthesized as enzyme inhibitors by the reaction of C3-beta-cholesteroalacrylate with heterocyclic di- and tri-ketones, the compounds are obtained as a single isomer in good yield through a stereo- and regioselective 1,3-dipolar cycloaddition methodology, method overview. Analysis of in vitro antibacterial activity, and inhibitory activity against highly pathogenic Gram-positive and Gram-negative bacteria. Automated in silico molecular docking analysis of cadidates in order to validate their effective orientation as inhibitors bound in the active site of glucosamine-6-phosphate synthase (1XFF) enzyme
-
additional information
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells
-
additional information
-
a series of covalent cholesterol-spiro pyrrolidine/pyrrolizidine heterocyclic hybrids possessing biologically active oxindole, indanedione, and acenaphthylene-1-one are synthesized as enzyme inhibitors by the reaction of C3-beta-cholesteroalacrylate with heterocyclic di- and tri-ketones, the compounds are obtained as a single isomer in good yield through a stereo- and regioselective 1,3-dipolar cycloaddition methodology, method overview. Analysis of in vitro antibacterial activity, and inhibitory activity against highly pathogenic Gram-positive and Gram-negative bacteria. Automated in silico molecular docking analysis of cadidates in order to validate their effective orientation as inhibitors bound in the active site of glucosamine-6-phosphate synthase (1XFF) enzyme
-